To examine the influence of compression garments manufactured with Far-Infrared technology on exercise performance during and after repeated eccentric isokinetic muscle actions of the leg extensors.

Start Date01 Feb 2014

Sponsor / Collaborator

The University of North Carolina at Chapel Hill

[+1]

100 Clinical Results associated with Solvay SA

0 Patents (Medical) associated with Solvay SA

3,516

Literatures (Medical) associated with Solvay SA

09 Aug 2023·SPE Journal

Evaluations of Polyacrylamide Water-Based Drilling Fluids for Horizontal Drilling in the Shaly Wolfcamp Formation

Author: Wiggins, H. ; Metwally, M. ; Saasen, A. ; Gipson, M. ; Yoo, H. ; Nguyen, T.

SummaryThe Permian Basin, located in southeastern New Mexico and west Texas, is treated as the largest province of oil and gas production in the United States (US). The majority of hydrocarbon production from the Permian Basin is from the Wolfcamp shaly formation. Drilling horizontal and extended reached wells is continuously increasing day after day in the Permian Basin. Oil-based mud (OBM) is used to drill these horizontal wells for enhancing shale inhibition, reducing torque and drag, and supporting thermal stability of mud rheology. Due to environmental regulation for limiting use of OBM, the petroleum industry has tried to develop water-based fluid (WBF) that approaches the performance advantages of OBM.The main objective of this research is to formulate and develop WBF by using polyacrylamide anionic friction reducer (AFR) for drilling the lateral sections of horizontal wells in the shaly Wolfcamp formation. Shale inhibition, barite sagging, lubricity, and thermal stability of the formulated WBF with AFR will be studied to evaluate the developed WBF. Laboratory experiments were conducted to develop and evaluate the performance of the formulated WBF with AFR. The shale inhibition capabilities of the developed WBF with AFR were evaluated by using zeta potential, shale dispersion test, and immersion test.The results prove the capability of the formulated WBF with AFR to prevent both shale swelling and shale dispersion. AFR limits water penetrations to shale through encapsulation. The mixing procedures of AFR with WBF affect both the thermal stability of mud rheology and shale inhibition. Adding AFR to WBF helps to suspend weighting materials and mitigate barite sag. Besides, AFR decreases torque and drag by decreasing the coefficient of friction (COF). Furthermore, AFR supports enhanced stability of mud rheology with time up to 14 days at temperatures up to 180°F.The formulated WBF with AFR can be used for enhancing shale inhibition, supporting thermal and time stability of fluid rheology, improving lubricity, and minimizing barite sagging for drilling shaly Wolfcamp formations. This study presents a promising WBF to replace OBM to drill lateral sections in the Permian Basin.

09 Aug 2023·SPE Reservoir Evaluation & Engineering

Smartwater Synergy with Chemical EOR: Studying the Potential Synergy with Surfactants

Author: Rousseau, David ; Sofi, Abdulkareem ; Ayirala, Subhash C. ; Wang, Jinxun ; Salaün, Mathieu ; Morvan, Mikel

SummaryThe potential synergy between smartwater and various enhanced oil recovery (EOR) processes has recently attracted significant attention. In previous work, we demonstrated such favorable synergy for polymer floods not only from a viscosity standpoint but also in terms of wettability. Recent studies suggest that smartwater synergy might even extend to surfactant floods. In this work, we investigate the potential synergy between smartwater and surfactant flooding. Opposed to previous work, the potential synergy is investigated from ground zero. We concurrently developed two surfactant formulations for conventional high-salinity injection water and low-salinity smartwater. To design the optimal surfactant-polymer (SP) formulations, we followed a systematic all-inclusive laboratory workflow. Oil displacement studies were performed in preserved core samples using the two developed formulations with conventional injection water and smartwater. The results demonstrated the promising potential of binary surfactant mixtures of olefin sulfonate (OS) and alkyl glyceryl ether sulfonate (AGES) for both waters. The designed binary formulations were able to form Winsor Type III emulsions besides achieving ultralow interfacial tensions (IFTs). Most importantly, in terms of oil displacement, the developed SP formulations in both injection water and low-salinity smartwater were capable of recovering more than 60% of the remaining oil post waterflooding. A key novelty of this work is that it investigates the potential synergy between smartwater and surfactant-based processes from the initial step of surfactant formulation design. Through well-designed from-scratch evaluation, we demonstrate that surfactant-based processes exhibit limited synergies with smartwater. Comparable processes in terms of performance can be designed for both high-salinity and low-salinity waters. It is also quite possible that the synergistic benefits of smartwater on oil recovery cannot be effective in SP flooding processes, especially with specific surfactant formulations under optimal salinity conditions.

01 Aug 2023·Progress in Rubber, Plastics and Recycling Technology

Compatibility of polyvinylidene chloride with mechanical recycling of polyolefins

Author: Ferrari, Domenico ; Vanderveken, Yves ; Mirenda, Marco ; Sanguineti, Aldo

The exceptional low permeability to oxygen and water of PVDC and the retention of barrier properties to oxygen even in humid conditions explain its success for packaging in food industry as barrier layer in Polyolefins (PO) multilayer films, whose contribution to the reduction of food waste is largely recognized. Several chemical recycling technologies have emerged in the recent years that, together with methodologies based on separation of layers by the use of solvents, will strongly increase in a near future the extent of recycling of multilayer films, including the PVDC-containing ones. At the same time, it is generally accepted that for several years these technologies will be complemented by the now dominating mechanical recycling. A lack of detailed study in the literature and a general confusion between very different PVDC grades, with and without internal stabilization, led to the idea that the dehydrochlorination of PVDC would cause a low quality of the recyclate obtained by mechanical recycling of PO in presence of PVDC and a corrosion risk for the equipment. In this study, the effect of a stabilized PVDC grade developed for coextrusion, at concentration typical of real life PO mix for mechanical recycling and in suitable condition, has been investigated in a pilot scale extruder and corrosion tests were performed. In conclusion, quantities of PVDC to be found in PO streams for mechanical recycling are compatible with a PO recyclate of excellent characteristics, even at extrusion temperatures as high as 220°C, with no damage to the PO structure, with only minimum discoloration, that can be mitigated by relatively low quantities of additives of general use in PO extrusion, and with no risk of corrosion of the equipment.

112

News (Medical) associated with Solvay SA

27 Sep 2024

·www.prnewswire.com

SELENA GOMEZ ANNOUNCES THE SECOND ANNUAL RARE IMPACT FUND BENEFIT SUPPORTING YOUTH MENTAL HEALTH

Selena Gomez will host her second annual Rare Impact Fund Benefit: A Night of Radiance & Reflection on October 24 in Los Angeles LOS ANGELES, Sept. 27, 2024 /PRNewswire/ -- Selena Gomez announced today that the second annual Rare Impact Fund Benefit, the annual fundraiser in support of the Rare Impact Fund, will be held on October 24 in Los Angeles. The star-studded benefit will feature live entertainment and special performances to be announced later. Now in its second year, the Rare Impact Fund Benefit: A Night of Radiance & Reflection aims to raise funds to support The Rare Impact Fund's mission to mobilize $100 million for organizations increasing access to youth mental health services and education globally. The Benefit will take place at Nya Studios West in Hollywood, California and will include food, drinks, world class entertainment, and a live auction. "I am so excited to host the second annual Rare Impact Fund Benefit here in Los Angeles and to continue building on the success of last year's inaugural event," shared Selena Gomez, Founder and Creator of Rare Beauty and the Rare Impact Fund. "Mental health advocacy and furthering the Rare Impact Fund's mission has become my life's work and I couldn't do this without the support of those around me. A heartfelt thank you to incredible friends and sponsors who passionately support our work." Selena Gomez launched the Rare Impact Fund in 2020 with the goal of raising $100 million to improve youth mental health around the world. As part of this commitment, Rare Beauty by Selena Gomez donates one percent of sales directly to the Rare Impact Fund and the Rare Impact Fund raises additional funds with Foundations, Corporate Partners, and individuals. The annual Rare Impact Fund Benefit plays a critical role in raising new funds. The Rare Impact Fund currently supports 26 youth mental health organizations across five continents, which includes organizations located in the United States, Canada, the United Kingdom, broader Europe, India, Brazil, and Australia. According to the World Economic Forum, mental ill-health affects one in four people, and around 20% of the world's children and adolescents. It has increased during the pandemic, compounded by being the most disrupted part of health systems across the world. Yet funding for mental health care remains extremely low – around 2% of global health funding and currently just 0.5% of philanthropic health giving. The mental health crisis is one of the most pressing issues facing young people today and continues to be severely underfunded. Elyse Cohen, EVP of Social Impact & Inclusion at Rare Beauty, and President of the Rare Impact Fund shared, "Funds raised from last year's inaugural Rare Impact Fund Benefit provided essential funding for the youth mental health organizations we support around the globe. These organizations are on the ground offering lifesaving tools and resources to over one million young people annually, which is all made possible by our partners, donors and community. This event has become the cornerstone of the Rare Impact Fund's fundraising efforts and helps us further our mission to reduce the stigma associated with mental health and increase access to mental health services and education." This non-traditional, cocktail style fundraiser welcomes a global community of mental health partners and guests, ranging from entertainment and business executives to celebrity friends and philanthropists, for an unforgettable night of impact, entertainment, and inspiration. Benefit attendees and the general public can support the Rare Impact Fund's mission by donating online at rareimpactfund.org or by visiting the online auction, now live, to bid on items and exclusive experiences like seats at New York Fashion Week and a luxury getaway to Montage Big Sky. Additional auction items will be added in the coming weeks with a live auction taking place during the benefit. Last year's inaugural event raised more than $2 million from over 20 sponsors and one-of-a-kind auction items from Taylor Swift, Airbnb, SoFi Stadium, and others. This year's Rare Impact Fund Benefit is made possible thanks to the generous support of our sponsors. Top-tier sponsors include Rare Beauty, SEPHORA, Wondermind, Abercrombie & Fitch, and Pacsun. For a full list of event sponsors who help make the evening possible, please visit the event site here. Ticket packages and sponsorship for the Rare Impact Fund Benefit are available for purchase. For information on ticket or sponsorship packages, please contact [email protected]. To bid on online auction items, visit: . ABOUT THE RARE IMPACT FUND The Rare Impact Fund was launched by Selena Gomez as part of her focus on addressing mental health. One percent of all Rare Beauty by Selena Gomez sales are donated to the Rare Impact Fund. The Rare Impact Fund raises additional funds with philanthropic foundations, individuals, corporate partners, and the Rare Beauty community. The Rare Impact Fund supports organizations that expand access to mental health services for young people. The Rare Impact Fund is a fiscally sponsored project of the Hopewell Fund, a 501(c)(3) public charity. To learn more about the Rare Impact Fund, visit rareimpactfund.org. SOURCE Rare Beauty WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

12 Sep 2024

·www.businesswire.com

EGLE Therapeutics Strengthens its Board of Directors with the Appointment of Michel Detheux, Ph.D., as Independent Chairman Board Member, and with the Appointment of Mojgan Hossein-Nia, Ph.D. as Board Member Representative of Takeda Ventures

PARIS--( BUSINESS WIRE )--EGLE Therapeutics, a clinical-stage biotechnology company uniquely positioned to advance the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, announced today the appointment of Michel Detheux Ph.D, as Chairman of the Board and Independent Board Member, and Mojgan Hossein-Nia as Director representative of Takeda Ventures. “We are thrilled to welcome Michel Detheux and Mojgan Hossein-Nia to our Board of Directors. Michel and Mojgan’s expertise and outstanding track record will be invaluable to Egle as we advance our clinical pipeline of novel therapies addressing the unmet medical need of patients with advanced cancer and autoimmune diseases. Their expertise in the field of oncology and their experience are instrumental for us to successfully execute on our strategic priorities, ” said Vincent Brichard, M.D., EGLE’s Interim CEO and Board member. “With the role of regulatory T cells becoming clearer in oncology and auto-immunity, I am excited to join the Board of Egle in order to help the team to move their differentiated pipeline toward a clinical proof of concept and help patients with innovative drugs targeting IL-2,” said Michel Detheux, independent chairman at Egle and CEO of iTeos Therapeutics. “ I am excited to join the Board of Egle in order to help the team strategize and continue to advance their pipeline to help patients in areas of unmet needs , ” said Mojgan Hossein-Nia, Board Member at Egle Therapeutics. Michel Detheux , Ph.D, Michel has held the role of Chief Executive Officer at iTeos Therapeutics since the company’s inception in 2012. During his tenure, Michel has led the company from its origins to NASDAQ listing, raising $335MM in 2020 through a crossover round and IPO. More recently, he spearheaded the strategic collaboration with GlaxoSmithKline in 2021 to co-develop and co-commercialize iTeos’ differentiated anti-TIGIT antibody for a total value of $2B. He previously served as a director at Ludwig Cancer Research and worked in various scientific and business development roles at Ogeda (f/k/a Euroscreen). Dr. Detheux holds a degree of Bio-engineer and a Ph.D. in Biochemistry from Université Catholique de Louvain, and a business certificate from Solvay Business School. Mojgan Hossein-Nia , Ph.D., Mojgan is the Head of R&D Global Portfolio Strategy and Strategic Finance, Research and Development at Takeda. She joined the company in September 2017 and currently directs portfolio strategy and management across all therapeutic areas facilitating investment decisions and overseeing R&D governance process. Additionally, she manages enabling capabilities that support portfolio management including the center of operational performance and integrated portfolio/finance digital solutions. In previous roles, she led the R&D investor relations group and built up the R&D Partnership Office, which was created to manage the overall health of R&D’s pipeline partnerships and their integration into R&D processes. Before joining Takeda, Mojgan worked at Novartis Pharmaceuticals, building and leading multiple global functions across R&D. Mojgan’s career spans over 30 years, comprising dedicated roles in development outsourcing, global program leadership and project management, business development & licensing, and across multiple therapeutic areas including cardiovascular, metabolism, and cell & gene therapies. Dr. Hossein-Nia holds a B.Sc, and Ph.D. in biochemistry from University of London, UK, and a diploma in pharmaceutical medicine from University of Surrey, UK. About Egle Therapeutics SAS (Egle) Egle Therapeutics is a biotechnology company focused on developing immunotherapies targeting suppressive regulatory T cells. Egle is leveraging a proprietary discovery platform to unveil novel Treg specific targets and to develop innovative Treg-focused drug candidates for oncology and autoimmune diseases. Egle aspires to advance toward the clinic its most advanced drug candidates, EGL-001 (a potential best-in-class Treg-selective anti-CTLA4-IL-2m) and EGL-003 (non-targeted IL-2 Treg engager), which are currently in IND-enabling studies. Find out more at www.egle-tx.com .

Executive ChangeIPOImmunotherapy

08 Aug 2024

·www.globenewswire.com

Aligos Therapeutics Strengthens Board with Two New Independent Directors

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced the appointment of Heather Preston, M.D. and Margarita Chavez, J.D. as Class II Independent Directors to the Board of Directors, effective August 7, 2024. Dr. Preston will join the Nominating and Corporate Governance Committee as Chair and Ms. Chavez will join the Audit Committee. “We are pleased to announce the appointment of Dr. Heather Preston and Margarita Chavez to our Board of Directors,” stated Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer of Aligos Therapeutics. “Both Heather and Margarita bring substantial expertise across the life sciences spectrum. We look forward to their important contributions towards ensuring Aligos’s success.” Heather Preston is an experienced healthcare investor and company builder, with more than 30 years of industry experience. She is currently a Senior Advisor to TPG Biotech and serves on the Boards of Oxford Biomedica (OXB:LSE), Oxford Nanopore Technologies (ONT:LSE), and Azura Opthalmics. Previously, she was a Managing Partner of Pivotal BioVentures and a Firm Partner and Managing Director of TPG Biotech. She also held investing roles at JP Morgan Partners and New Enterprise Associates. Prior to her investing career, Dr. Preston spent five years at McKinsey & Co, where she was a leader of their pharmaceutical and medical products consulting practice. Dr. Preston has an undergraduate degree in biochemistry from the University of London and a medical degree from the University of Oxford. Dr. Preston completed a post-doctoral fellowship in molecular biology at the Dana Farber Cancer Institute, Harvard University and trained in Internal Medicine at the Massachusetts General Hospital and subspecialized in Gastroenterology and Hepatology at UCSF. During her academic medical career, she was the recipient of a Fulbright Scholarship, a Fulbright Cancer Research Scholarship, a Harlech Scholarship and a Science and Engineering Research Council Post-Doctoral Fellowship Award. “I am thrilled to join the Board at Aligos,” stated Dr. Heather Preston. “This is an exciting time as Aligos has two potential best-in-class oral drugs for MASH and CHB. I look forward to the opportunity of working with the other Board members and the Senior Leadership Team as the Company continues to progress its promising drug candidates through the clinic.” Margarita Chavez is a seasoned biopharmaceutical executive, with over 25 years of dealmaking experience in the healthcare industry. She is currently a Venture Partner at Wellington Partners and is an independent investor and advisor in early-stage biotechs. Margarita also currently serves on the Board of Newron Pharmaceuticals (NWRN:SIX). Margarita was previously Managing Director at AbbVie Ventures and was responsible for investments in Morphic Therapeutics, Alector Therapeutics, Carisma Therapeutics, Jnana Therapeutics, Enthera Pharmaceutials, Palleon Pharmaceuticals, and Accent Therapeutics, among others. As a Director on the Licensing & Acquisitions team of Abbott / AbbVie, Margarita was involved in the in-licensing of Oralissa, and the acquisitions of Immuven and Solvay. Early in her career, Margarita practiced as a corporate and securities lawyer, advising clients on mergers, acquisitions, public and private financings at Brobeck, Phleger & Harrison LLP in Silicon Valley. Outside of her venture work, Margarita serves on the Board of Regents at Santa Clara University and on the Board of P33 Chicago. “I look forward to collaborating with the Board to guide the team at Aligos to continue delivering for shareholders and patients in need,” stated Margarita Chavez, J.D. “Aligos’ dedication to science in order to bring the best drug candidates forward is a mission that I look forward to supporting.” About Aligos Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of liver and viral diseases. Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver and viral diseases to discover and develop potentially best-in-class therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and viruses with high unmet medical need such as hepatitis B and coronaviruses. For more information, please visit www.aligos.com or follow us on LinkedIn or X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2024 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events. Aligos Therapeutics Contact Jordyn TaraziVice President, Investor Relations & Corporate Communications+1 (650) 910-0427jtarazi@aligos.com

Executive Change

100 Deals associated with Solvay SA

100 Translational Medicine associated with Solvay SA

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 26 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Approved

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Fluvoxamine Maleate ( SERT )	Obsessive-Compulsive Disorder More	Approved
Stepronin	Respiration Disorders More	Approved
Tedisamil Sesquifumarate ( Potassium channel )	Atrial Flutter More	Approved
Esterified estrogens/Methyltestosterone ( AR x ER )	Hot Flashes More	Approved
Dydrogesterone ( PR )	Endometriosis More	Approved

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis